Madaras-Kelly Karl J, Remington Richard E, Lewis Pamela G, Stevens Dennis L
Clinical Pharmacy Service, Boise VA Medical Center, Boise, ID 83702, USA.
Infect Control Hosp Epidemiol. 2006 Feb;27(2):155-69. doi: 10.1086/500060. Epub 2006 Feb 8.
Society for Health Care Epidemiology guidelines recommend decreasing the use of fluoroquinolone antibiotics in institutions where methicillin-resistant Staphylococcus aureus (MRSA) is endemic. We evaluated whether an intervention to limit fluoroquinolone use was associated with a lower rate of nosocomial MRSA infection and summarized changes in antibiotic use, changes in other variables potentially correlated with a lower rate of MRSA infection, and rates of nosocomial infections due to other pathogens.
Single-center quasi-experimental design. A time series of nosocomial MRSA infections was measured at monthly intervals from July 2001 through June of 2004; there were 80 MRSA infections recorded. Segmented regression analysis (ie, quasi-Poisson generalized linear models) was used to evaluate variables possibly associated with the nosocomial MRSA infection rate.
An 87-bed Veterans Affairs teaching hospital with an extended-care facility.
A physician-directed computer-generated intervention designed to limit the use of fluoroquinolone antibiotics was initiated, and institutional changes in antibiotic use and nosocomial MRSA infection rates were tracked.
After the intervention, fluoroquinolone use decreased by approximately 34%, and levofloxacin use decreased by approximately 50%. Decreased fluoroquinolone use was offset by increased cephalosporin, piperacillin-tazobactam, and trimethoprim-sulfamethoxazole use. The nosocomial MRSA infection rate decreased from 1.37 to 0.63 episodes per 1,000 patient-days after the study intervention (P=.02). Coagulase-negative Staphylococcus and Enterococcus infection rates also decreased. However, the rate of infection with gram-negative organisms increased. The rate of MRSA infection was positively correlated with levofloxacin use (P=.01) and azithromycin use (P=.08), whereas it was negatively correlated with summer season (P=.05). In a subsequent model, the rate of MRSA infection was negatively correlated with the study intervention (P=.04).
Reduction in the institutional use of fluoroquinolones may be associated with a lower nosocomial MRSA infection rate.
医疗保健流行病学学会指南建议,在耐甲氧西林金黄色葡萄球菌(MRSA)流行的机构中减少氟喹诺酮类抗生素的使用。我们评估了限制氟喹诺酮使用的干预措施是否与较低的医院获得性MRSA感染率相关,并总结了抗生素使用的变化、其他可能与较低MRSA感染率相关的变量的变化,以及其他病原体导致的医院感染率。
单中心准实验设计。从2001年7月至2004年6月,每月对医院获得性MRSA感染进行一次时间序列测量;共记录了80例MRSA感染。采用分段回归分析(即准泊松广义线性模型)来评估可能与医院获得性MRSA感染率相关的变量。
一家拥有87张床位的退伍军人事务教学医院及一家延伸护理机构。
启动了一项由医生指导的计算机生成的干预措施,旨在限制氟喹诺酮类抗生素的使用,并跟踪抗生素使用和医院获得性MRSA感染率的机构变化。
干预后,氟喹诺酮的使用量减少了约34%,左氧氟沙星减少了约50%。氟喹诺酮使用量的减少被头孢菌素、哌拉西林-他唑巴坦和甲氧苄啶-磺胺甲恶唑使用量的增加所抵消。研究干预后,医院获得性MRSA感染率从每1000患者日1.37例降至0.63例(P=0.02)。凝固酶阴性葡萄球菌和肠球菌感染率也有所下降。然而,革兰氏阴性菌的感染率有所上升。MRSA感染率与左氧氟沙星的使用量呈正相关(P=0.01),与阿奇霉素的使用量呈正相关(P=0.08),而与夏季呈负相关(P=0.05)。在随后的模型中,MRSA感染率与研究干预呈负相关(P=0.04)。
机构内氟喹诺酮类药物使用的减少可能与较低的医院获得性MRSA感染率相关。